Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: StockMiser who wrote (529)	3/26/1999 3:55:00 PM
From: tuck	Read Replies (1) \| Respond to of 2515

StockMiser, A well-supported response. But we're still talking early stage research being presented, are we not? It can certainly support the stock, but is unlikely to move it unless it's perceived as groundbreaking in big markets. This is all I'm saying. Cheers, Tuck

To: StockMiser who wrote (529)	3/28/1999 2:34:00 AM
From: Tim Williams	Respond to of 2515

StockMiser, thanks for the references. I'm not a clinical researcher but the abstracts I've read, IMHO, sure make me think C225 is going to be winner. I thought the abstract on pancreatic cancer was a positive. Pancreatic cancer has a very poor prognosis and any treatment that shows promise would surely have rapid market penetration. Research on renal cell cancer is due out soon and hopefully we'll see some research on C225 in lung and colorectal cancer before long.